분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-11-21 13:26:10 , Hit : 1220
 Cost to Develop a Drug More Than Doubles to $2.56 Billion


By Anna Edney Nov 19, 2014 12:30 AM GMT+0900Email Print Speed

  It costs drugmakers $2.56 billion to bring a new medicine to market, on average, more than double the price of 11 years ago, according to a study released today.

The higher cost comes from clinical trials that are larger and more complex, as well as more drugs that fail in development, according to the researchers. While the Food and Drug Administration is sometimes blamed for driving up costs because of the time it takes to review new drugs, that wasn’t a factor, according to the study by the Tufts Center for the Study of Drug Development.

“Drug development remains a costly undertaking despite ongoing efforts across the full spectrum of pharmaceutical and biotech companies to rein in growing R&D costs,” Joseph DiMasi, director of economic analysis at the Boston-based center, said in a statement.

Drug and biotechnology companies have come under pressure from lawmakers and health insurance companies to justify the costs of of their products. It’s a long-running debate that’s been reignited with the introduction of treatments like Gilead Sciences Inc.’s hepatitis C pill, Harvoni, which costs $94,500 for a 12-week course. The new drugs are the product of breakthrough science -- and come with breakthrough price tags.

As of the Tufts Center’s last estimate, in 2003, it cost $1.04 billion in 2013 dollars to develop a new brand-name drug. About 40 percent of the center’s funding comes from drug companies, with the rest from research grants and educational course fees.

Industry Attack
The health insurance lobby has repeatedly attacked the drug industry’s prices. America’s Health Insurance Plans, the industry’s Washington-based trade group, sends out weekly, if not daily, e-mails slamming drugmakers for relying on development costs to back the high price of pharmaceuticals.

“It’s become increasingly clear that drug prices are no longer driven by development costs,” Brendan Buck, a spokesman for AHIP, said in a Nov. 17 e-mail. “They’re set by whatever the drugmakers think they can get away with.”

Drugmakers have fired back that drug treatments are often cheaper than surgery or hospital care patients can require without them, and point out that other health-care spending makes up a far bigger part of costs.

The Tufts Center for the Study of Drug Development based its finding on data from the experiences of 10 drug companies and 106 experimental products. Eighty-seven of the products were less complex chemical drugs; the rest were more complex biologic drugs that are manufactured from living organisms.

The costs of development don’t always end after a drug is approved. The FDA can require new studies to get more data on safety and effectiveness, or the drugmaker can conduct trials to expand use of the medicine. Those post-approval studies add $312 million to a drug’s cost, raising the development price tag to $2.87 billion, according to the study.

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net

To contact the editors responsible for this story: Crayton Harrison at tharrison5@bloomberg.net Drew Armstrong, John Lear


Press spacebar to pause and continue. Press esc to stop.







1087   부모의 특징을 자식에게 전달하는 방식: 박테리아의 DNA  이성욱 2015/02/19 1192
1086   에볼라 확산원인에 대한 새로운 주장  이성욱 2015/01/06 1194
1085   융합연구리뷰 | Convergence Research Review  이성욱 2016/01/08 1194
1084   생명과학 연구에서 암컷쥐가 필요한 이유  이성욱 2015/07/23 1196
1083   인류의 역사를 고스란히 보여주는 결핵균의 게놈  이성욱 2015/01/21 1203
1082   [바이오토픽] 브로드 연구소, 열띤 CRISPR 특허전쟁에서 승리  이성욱 2017/02/16 1206
1081   유전자치료제 연구개발 및 규제 동향 2015-식품의약품안전처  이성욱 2016/01/20 1211
1080   의문이 제기된 `젊은 피`의 항노화 효과  이성욱 2015/05/22 1216
  Cost to Develop a Drug More Than Doubles to $2.56 Billion  이성욱 2014/11/21 1220
1078   FDA approves 9-valent HPV vaccine for certain cancers  이성욱 2014/12/12 1225
1077   Gilead wins European approval of next-generation hepatitis C drug  이성욱 2014/11/20 1226
1076   정밀의학의 끝: 개인화된 종양백신을 개발하는 과학자들  이성욱 2016/04/26 1227
1075   특허전쟁: 미국 특허청, CRISPR의 특허권 중재 시작  이성욱 2016/03/08 1228
1074   미국 과학·공학·의학 아카데미, 「GM 베이비」의 진행방향에 대한 윤곽 발표  이성욱 2017/02/16 1228
1073   세계 20여 개국 과학자들, 유전자편집 정상회담 개최  이성욱 2015/12/05 1232
1072   CRISPR의 능력을 배가(倍加)시키는 미니 유전자  이성욱 2015/04/02 1235
1071   Janssen, Isis Pharma Ink Up-to-$835M Antisense Agreement  이성욱 2015/01/07 1237
1070   줄기세포로 만든 초기 난자와 정자  이성욱 2014/12/31 1240
1069   맹인을 위한 유전자치료의 쇠퇴  이성욱 2015/05/08 1248
1068   유전자편집치료에 희망을 준 백혈병치료  이성욱 2015/11/11 1248

[1][2][3][4][5][6][7][8][9] 10 ..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN